Pfizer slams CMA’s “political” excessive-pricing decision

A lawyer for Pfizer today said the UK antitrust enforcer’s decision to fine the company for excessive pricing of an anti-epilepsy drug was “price regulation, pure and simple”, and attacked the agency’s refusal to examine comparable drugs when assessing Pfizer’s phenytoin prices.


Get unlimited access to all Global Competition Review content